臨床検査54巻3号

2010年03月発行

記事購入ページに移動

今月の主題 骨髄増殖性疾患 各論 〈治療―治療方針・治療成績・予後〉

原発性骨髄線維症

著者： 石澤丈¹ 岡本真一郎¹

所属機関： ¹慶應義塾大学医学部血液内科

ページ範囲：P.293 - P.298

　原発性骨髄線維症は平均生存期間3～5年の難治進行性疾患であり，血球減少に伴う感染症や出血，脾腫，白血化，門脈圧亢進などを主要な臨床像とする病態である．その治療は症状軽減のための対症療法と根治を目的とした同種造血幹細胞移植に大別される．しかし，最近ではJAK2 V617Fに代表されるJAK/STAT経路を恒常的に活性化する遺伝子変異が一部の症例において病態の根幹をなすことが示され，多くの分子標的治療薬が臨床研究の段階に躍進した．本稿では，原発性骨髄線維症における対症療法の意義・同種造血幹細胞移植成績と適応，そして新規治療薬の現状につき概説する．

参考文献

1) Dupriez B, Morel P, Demory JL, et al：Prognostic factors in agnogenic myeloid metaplasia：a report on 195 cases with a new scoring system. Blood　88：1013-1018, 1996

2) Rambaldi A, Barbui T, Barosi G：From palliation to epigenetic therapy in myelofibrosis. Hematology Am Soc Hematol Educ Program　2008：83-91

3) Dingli D, Schwager SM, Mesa RA, et al：Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis. Cancer　106：1985-1989, 2006

4) Mesa RA, Tefferi A：Surgical and radiotherapeutic approaches for myelofibrosis with myeloid metaplasia. Semin Oncol　32：403-413, 2005

5) Ciurea SO, Sadegi B, Wilbur A, et al：Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation. Br J Haematol　141：80-83, 2008

6) Shimoda K, Shide K, Kamezaki K, et al：The effect of anabolic steroids on anemia in myelofibrosis with myeloid metaplasia：retrospective analysis of 39 patients in Japan. Int J Hematol　85：338-343, 2007

7) Cervantes F, Alvarez-Larrán A, Hernández-Boluda JC, et al：Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia：results in 20 patients and review of the literature. Br J Haematol　127：399-403, 2004

8) Guardiola P, Anderson JE, Bandini G, et al：Allogeneic stem cell transplantation for agnogenic myeloid metaplasia：a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood　93：2831-2838, 1999

9) Rondelli D, Barosi G, Bacigalupo A, et al：Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate-or high-risk patients with myelofibrosis with myeloid metaplasia. Blood　105：4115-4119, 2005

10) Kröger N, Zabelina T, Schieder H, et al：Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Haematol　128：690-697, 2005

11) Snyder DS, Palmer J, Stein AS, et al：Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis. Biol Blood Marrow Transplant　12：1161-1168, 2006

12) Mesa RA, Steensma DP, Pardanani A, et al：A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood　101：2534-2541, 2003

13) Abgrall JF, Guibaud I, Bastie JN, et al：Thalidomide versus placebo in myeloid metaplasia with myelofibrosis：a prospective, randomized, double-blind, multicenter study. Haematologica　91：1027-1032, 2006

14) Tefferi A, Cortes J, Verstovsek S, et al：Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood　108：1158-1164, 2006

15) Quintás-Cardama A, Kantarjian HM, Manshouri T, et al：Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol　27：4760-4766, 2009

16) Giles FJ, List AF, Carroll M, et al：PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor(VEGF), has modest activity in myelofibrosis with myeloid metaplasia. Leuk Res　31：891-897, 2007

17) Wernig G, Kharas MG, Okabe R, et al：Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell　13：311-320, 2008

18) Verstovsek S, Pardanani AD, Shah NP, et al：A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis and post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood(ASH Annual Meeting Abstracts)　110：553, 2007

19) Verstovsek S, Kantarjian H, Pardanani A, et al：INCB018424, an oral, selective JAK2 inhibitor, shows significant clinical activity in a phase I/II study in patients with primary myelofibrosis(PMF)and post polycythemia vera/essential thrombocythemia myelofibrosis(Post-PV/ET MF). Blood(ASH Annual Meeting Abstracts)　110：558, 2007

20) Quintás-Cardama A, Tong W, Kantarjian H, et al：A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Leukemia　22：965-970, 2008

21) Mesa RA, Camoriano JK, Geyer SM, et al：A phase II trial of tipifarnib in myelofibrosis：primary, post-polycythemia vera and post-essential thrombocythemia. Leukemia　21：1964-1970, 2007